Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of …
J Meng, H Tang, Y Xiao, W Liu, Y Wu… - … Journal of Surgery, 2024 - journals.lww.com
Background: There was controversy surrounding the optimal thromboprophylaxis strategy
for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of …
for coronavirus disease 2019 (COVID-19) patients. This included debates on the dosage of …
[HTML][HTML] Prophylactic-dose direct oral anticoagulants for non-hospitalised people with COVID-19: A meta-analysis of randomised controlled trials
Q Song, H Liu, H Tan, B Yang, H Zhang… - Journal of Global …, 2024 - ncbi.nlm.nih.gov
Background Several reviews have been conducted on thromboprophylaxis in non-
hospitalised patients with coronavirus disease 2019 (COVID-19). In this systematic review …
hospitalised patients with coronavirus disease 2019 (COVID-19). In this systematic review …
[HTML][HTML] 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
S Schulman, DM Arnold, CA Bradbury… - Journal of thrombosis …, 2024 - Elsevier
Based on emerging evidence from the COVID-19 pandemic, the International Society on
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …
Incidence and individual risk prediction of post-COVID-19 cardiovascular disease in the general population: a multivariable prediction model development and …
HM la Roi-Teeuw, M van Smeden… - … Heart Journal Open, 2023 - academic.oup.com
Aims Previous studies suggest relatively increased cardiovascular risk after COVID-19
infection. This study assessed incidence and explored individual risk and timing of …
infection. This study assessed incidence and explored individual risk and timing of …
Rivaroxaban Plasma Concentration and Clinical Outcomes on Older Patients with Non-valvular Atrial Fibrillation and Pulmonary Infection
Y Yu, H Li, J Liu, Q Liang, J Xie, G Sun - American Journal of …, 2024 - Springer
Introduction Infection may induce thrombotic and hemorrhagic events; however, it is
currently unclear whether the inflammatory response affects the coagulation function and the …
currently unclear whether the inflammatory response affects the coagulation function and the …
Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials
J Hsia, AC Spyropoulos, G Piazza… - Thrombosis and …, 2023 - thieme-connect.com
Background We conducted a prespecified meta-analysis of two randomized, placebo-
controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute coronavirus …
controlled trials of rivaroxaban 10 mg daily in prehospital patients with acute coronavirus …
Anticoagulation in COVID-19 patients–An updated systematic review and meta-analysis
S Reis, A Faske, I Monsef, F Langer, OJ Müller… - Thrombosis …, 2024 - Elsevier
Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …
[HTML][HTML] Effectiveness and safety of rivaroxaban for anticoagulation therapy in COVID-19: A meta-analysis of randomized controlled trials
X Shen, E Qiu, Z Liu, X Zhu, Y Zeng - Saudi Medical Journal, 2024 - ncbi.nlm.nih.gov
Objectives: To evaluate the effectiveness and safety of rivaroxaban anticoagulation in
COVID-19 patients. Methods: PubMed, Embase, Cochrane Library electronic databases …
COVID-19 patients. Methods: PubMed, Embase, Cochrane Library electronic databases …
O uso dos Anticoagulantes Orais de Ação Direta (DOACs) como terapia anticoagulante na COVID-19
EM Sousa, GEF Neto, HM Lobo… - Revista Eletrônica …, 2024 - acervomais.com.br
Objetivo: Identificar os efeitos da utilização dos Anticoagulantes Orais de Ação Direta
(DOACs) na infecção pelo SARS-CoV-2 como terapia anticoagulante no curso da doença …
(DOACs) na infecção pelo SARS-CoV-2 como terapia anticoagulante no curso da doença …
[PDF][PDF] Antithrombotic therap in the Netherlands: ne insights from nation ide data
Q Chen - Thromb Haemost, 2022 - scholarlypublications …
[5] Toorop MMA, Chen Q, Kruip M, van der Meer FJM, Nierman MC, Faber L, et al. Switching
from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation …
from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation …